Medtronic MiniMed Paradigm REAL-Time Veo Insulin Pump Recall
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Medtronic MiniMed, Inc. is recalling 55,724 units of Paradigm REAL-Time Veo Insulin Pumps due to potential over- or under-delivery of insulin caused by gravitational forces.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on April 14, 2026 and geographically references United States and Worldwide. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, cpsc, Devices.
What Happened
Medtronic MiniMed, Inc. is recalling certain insulin pumps because they may over-deliver or under-deliver insulin when the pump is elevated or lowered relative to the infusion site, due to changes in gravitational force affecting pressures. This issue can lead to severe health risks including hypoglycemia, hyperglycemia, seizure, coma, diabetic ketoacidosis, or death.
Which Products Are Affected
The affected products are the Paradigm REAL-Time Veo Insulin Pump with models MMT-554 and MMT-754. A total of 55,724 units are involved in this recall. Distribution occurred nationwide in the United States, including states such as OR, CA, AZ, NY, TX, FL, OH, MO, TN, NJ, NC, SC, IL, VA, WA, DC, GA, PA, MS, IA, MI, NH, OK, SD, MT, WI, WV, MA, LA, MN, RI, AR, ME, AL, IN, UT, KY, CO, ND, MD, CT, NM, KS, ID, NV, DE, NE, VT, AK, HI, WY, PR, VI, and worldwide in countries including Taiwan, Australia, Canada, and many others. The recall number is Z-1752-2026, and it was initiated on February 13, 2026.
What You Should Do
Consumers who have the affected pumps should follow the initial firm notification, which was issued via letter, and contact Medtronic MiniMed, Inc. for further instructions on the recall process, including potential returns or refunds.
Why This Matters
This recall addresses a serious safety issue with insulin delivery that could result in life-threatening conditions for users, highlighting the importance of proper medical device function in diabetes management.
Source
Attribution: FDA. For more information, visit the FDA website at the recall page for event ID 98186.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,626 characters here).
Similar severity timing
Same severity (high) notices issued closest in time to April 14, 2026.
Frequently Asked Questions
Common questions about this FDA recall.